Want to see CAI full AI Analyst Report?
Total Valuation
Caris Life Sciences, Inc. has a market cap or net worth of $6.95B. The enterprise value is $4.70K.
Market Cap$6.95B
Enterprise Value$4.70K
Share Statistics
Caris Life Sciences, Inc. has 282,595,180 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding282,595,180
Owned by Insiders49.13%
Owned by Institutions19.80%
Financial Efficiency
Caris Life Sciences, Inc.’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is 4.52%.
Return on Equity (ROE)-0.93
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)4.52%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee439.89K
Profits Per Employee-36.88K
Employee Count1,846
Asset Turnover0.72
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Caris Life Sciences, Inc. is 70.6. Caris Life Sciences, Inc.’s PEG ratio is 0.48.
PE Ratio70.6
PS Ratio9.38
PB Ratio13.19
Price to Fair Value13.19
Price to FCF113.87
Price to Operating Cash Flow36.89
PEG Ratio0.48
Income Statement
In the last 12 months, Caris Life Sciences, Inc. had revenue of 812.03M and earned -537.96M in profits. Earnings per share was -1.91.
Revenue812.03M
Gross Profit539.17M
Operating Income45.11M
Pretax Income-68.09M
Net Income-537.96M
EBITDA11.38M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was 201.43M and capital expenditures -54.94M, giving a free cash flow of 146.49M billion.
Operating Cash Flow201.43M
Free Cash Flow146.49M
Free Cash Flow per Share0.52
Dividends & Yields
Caris Life Sciences, Inc. pays an annual dividend of $0.3, resulting in a dividend yield of ―
Dividend Per Share$0.3
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.19
52-Week Price Change-33.16%
50-Day Moving Average31.76
200-Day Moving Average―
Relative Strength Index (RSI)34.86
Average Volume (3m)3.14M
Important Dates
Caris Life Sciences, Inc. upcoming earnings date is Nov 11, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Caris Life Sciences, Inc. as a current ratio of 7.85, with Debt / Equity ratio of 76.45%
Current Ratio7.85
Quick Ratio7.85
Debt to Market Cap0.05
Net Debt to EBITDA-36.80
Interest Coverage Ratio0.79
Taxes
In the past 12 months, Caris Life Sciences, Inc. has paid 469.87M in taxes.
Income Tax469.87M
Effective Tax Rate-6.90
Enterprise Valuation
Caris Life Sciences, Inc. EV to EBITDA ratio is 632.55, with an EV/FCF ratio of 107.61.
EV to Sales8.86
EV to EBITDA632.55
EV to Free Cash Flow107.61
EV to Operating Cash Flow86.57
Balance Sheet
Caris Life Sciences, Inc. has $793.12M in cash and marketable securities with $452.40M in debt, giving a net cash position of $340.71M billion.
Cash & Marketable Securities$793.12M
Total Debt$452.40M
Net Cash$340.71M
Net Cash Per Share$1.21
Tangible Book Value Per Share$1.98
Margins
Gross margin is 69.66%, with operating margin of 5.56%, and net profit margin of -66.25%.
Gross Margin69.66%
Operating Margin5.56%
Pretax Margin-8.38%
Net Profit Margin-66.25%
EBITDA Margin1.40%
EBIT Margin-1.38%
Analyst Forecast
The average price target for Caris Life Sciences, Inc. is $26.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$26.29
Price Target Upside69.37% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast85.37%
EPS Growth Forecast―